Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment

Published byCurtis McBride Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment"— Presentation transcript:

1 Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment
Alemtuzumab-induced changes in the dendritic cell compartment (A) Gating strategy for dendritic cells. Peripheral blood mononuclear cells (PBMCs) were gated by forward scatter vs side scatter characteristics. Lineage (CD3, CD14, CD19) negative cells expressing human leukocyte antigen–DR (HLA-DR) were further categorized into CD141+ conventional DCs, CD1c+ conventional DCs, and CD303+ plasmacytoid dendritic cells (pDCs). (B) Graphs display proportions of Lin−HLA-DR+ cells within PBMCs or the respective dendritic cell (DC) subsets within Lin−HLA-DR+ (upper row) and total cell numbers (lower row) of DC subsets derived from alemtuzumab-treated patients with relapsing-remitting multiple sclerosis (n = 12) at baseline (filled triangles) and 6-month follow-up (open triangles). p Values were calculated by paired Student t test or Wilcoxon matched-pairs signed rank test, respectively, *p < 0.05, **p < 0.01, ***p < Catharina C. Gross et al. Neurol Neuroimmunol Neuroinflamm 2016;3:e289 © 2016 American Academy of Neurology

Download ppt "Figure 2 Alemtuzumab-induced changes in the dendritic cell compartment"

Similar presentations

SSC -A SLAN CD16 CD14 CD3-CD19-CD56 CD123 HLA-DR CD33

SSC -A SLAN CD16 CD14 CD3-CD19-CD56 CD123 HLA-DR CD33
Side Scatter Forward Scatter Lineage CD1c CD141 CD303 lineage negative

Side Scatter Forward Scatter Lineage CD1c CD141 CD303 lineage negative
Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)

Figure 2 ALSFRS-R changes (A) Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) slope after 6 months of treatment without (left)
by Venetia Bigley, Laura E. Spence, and Matthew Collin

by Venetia Bigley, Laura E. Spence, and Matthew Collin
Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.
Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.

Figure 3 B-cell amount and the frequency of various B-cell subtypes are differentially affected by FTY or DMF treatment B-cell amount and the frequency.
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.
Omalizumab treatment downregulates dendritic cell FcεRI expression

Omalizumab treatment downregulates dendritic cell FcεRI expression
Figure 4 Relation of neuropsychological deficits and intrathecal immune cell subsets in GABAB receptor antibody–associated limbic encephalitis Relation.

Figure 4 Relation of neuropsychological deficits and intrathecal immune cell subsets in GABAB receptor antibody–associated limbic encephalitis Relation.
Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.

Figure 1 Treg percentage and suppressive function increased during each round of Treg infusions Treg percentage and suppressive function increased during.
Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.

Figure 5 Treatment with fingolimod raises the activation threshold of monocytes in MS Peripheral blood mononuclear cells from 8 healthy donors, 7 patients.
Figure 3 JCV index changes in JCV+ patients

Figure 3 JCV index changes in JCV+ patients
Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.

Figure 2 The frequency of helper T cells (Th) within CD4+ population and TCRγδ within CD3+ cells is affected by FTY and DMF treatment The frequency of.
Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Effect of DMF therapy on T cell subsets
Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.

Figure 4 Abundance of cytokines which showed significant difference in expression in the plasma and the cultured PBMC of patients with RRMS Abundance of.
Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.

Figure 2 Elevated antibody reactivities against myelin and Epstein-Barr virus (EBV) peptides in relapsing-remitting multiple sclerosis (RRMS) and higher.
Figure 2 Logistical requirements for autologous

Figure 2 Logistical requirements for autologous
Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.

Figure 1 The abundance of CD3+ T cells and their subtypes are significantly affected by FTY and DMF treatment The abundance of CD3+ T cells and their subtypes.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Similar presentations

Ads by Google